Determination of megestrol acetate and cyproterone acetate in serum of patients with advanced breast cancer by high-performance liquid chromatography.
A reversed-phase high-performance liquid chromatographic method with ultraviolet detection of megestrol acetate and cyproterone acetate in human sera is described. The proposed assay is linear up to 1400 ng/ml (r = 0.999) and has a detection limit of 5 ng/ml. Recoveries of both compounds in spiked sera were ca. 95%; inter-assay coefficients of variation were 4.0 and 3.1% and intra-assay values were 1.3 and 1.4%, respectively. For validation of the method we also developed a gas chromatographic-mass spectrometric method for both steroids. The results obtained by the two methods showed good correlation: for megestrol acetate r = 0.98, n = 31, p less than 0.0001, and for cyproterone acetate r = 0.94, n = 0, p less than 0.0001. Large inter-individual differences in the serum concentrations of both substances were found in groups of patients with metastatic breast cancer receiving the same oral load of either steroid.
Dikkeschei
L D
LD
Central Laboratory for Clinical Chemistry, University Hospital, Groningen, The Netherlands.
Wolthers
B G
BG
de Ruyter-Buitenhuis
A W
AW
Nagel
G T
GT
Sleijfer
D T
DT
Willemse
P H
PH
van der Slik
W
W
D000970:Antineoplastic Agents / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood*; D002851:Chromatography, High Pressure Liquid; D003534:Cyproterone / Q000031:analogs & derivatives* / Q000097:blood; D017373:Cyproterone Acetate; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D008535:Megestrol / Q000031:analogs & derivatives* / Q000097:blood; D019290:Megestrol Acetate
D000970:Antineoplastic Agents; D017373:Cyproterone Acetate; D003534:Cyproterone; D008535:Megestrol; D019290:Megestrol Acetate